Text Size

Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00346008
First received: June 27, 2006
Last updated: February 18, 2009
Last verified: December 2008
History of Changes

June 27, 2006
February 18, 2009
October 2005
December 2008   (final data collection date for primary outcome measure)
  • Feasibility to identify melanoma [ Designated as safety issue: No ]
  • Feasibility to detect mutation [ Designated as safety issue: No ]
  • Ability to create datasets [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00346008 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members
Genetic Epidemiologic Studies of Melanoma in Iceland

RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer.

PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.

OBJECTIVES:

  • Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in Iceland.
  • Assess the feasibility of mutation detection using sequencing and HPLC.
  • Determine UVS' ability to create datasets with demographic, epidemiologic and molecular data.

OUTLINE: Participants and patients undergo blood collection and complete lifestyle questionnaires. All patients and population-based controls have DNA samples sequenced for MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.
Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Melanoma (Skin)
  • Genetic: mutation analysis
  • Other: high performance liquid chromatography
  • Other: laboratory biomarker analysis
  • Other: questionnaire administration
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2500
Not Provided
December 2008   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Patients diagnosed with melanoma and selected family members are eligible to participate
  • Must live in Iceland

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
Not Provided
Yes
Contact information is only displayed when the study is recruiting subjects
Iceland
 
NCT00346008
CDR0000551606, NCI-06-C-N026, NBCI-03-033-CM, NBCI-01-087-CM, 999906026
Not Provided
Not Provided
Iceland Genomics Corporation
National Cancer Institute (NCI)
Study Chair: Alisa Goldstein, PhD National Cancer Institute (NCI)
National Cancer Institute (NCI)
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP